Publications by authors named "Lauren A George"
Background: In ulcerative colitis (UC), endoscopic improvement, defined as a Mayo Endoscopic Score (MES) of 0 or 1, is a target of treatment. The aim of our study was to evaluate the risk of clinical relapse between patients with an MES of 0 or 1 and determine if histologic activity using the Robarts Histopathologic Index (RHI) was predictive of clinical relapse.
Methods: UC patients with an MES score of 0 or 1, no prior colectomy, and at least 1 year of outpatient follow-up after colonoscopy were included.
Article Synopsis
- The study evaluated how well patients with inflammatory bowel disease (IBD) adhered to biologic therapy and examined the factors affecting their adherence at academic centers with integrated specialty pharmacies.
- Researchers analyzed data from 608 patients aged ≥18, measuring medication possession ratio (MPR) and the impact of factors like smoking, narcotic use, and psychiatric history on adherence.
- Results showed high adherence rates (68%-70%), but more risk factors increased the likelihood of nonadherence, which was linked to a higher risk of emergency department visits and hospitalizations.
Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form).
Gastroenterol Clin North Am
December 2020
Corticosteroids are a nonspecific immune modulator used in the treatment of ulcerative colitis. Topical and systemic forms of corticosteroids have been shown to be effective in induction of clinical remission and remain first-line therapy for acute severe ulcerative colitis. A large proportion of patients experience adverse effects, however, including some serious adverse effects, including infection and increased mortality.
View Article and Find Full Text PDFTelemedicine in gastroenterology in the wake of COVID-19.
Expert Rev Gastroenterol Hepatol
November 2020
Integration of telemedicine into clinical practice for inflammatory bowel disease.
Curr Opin Gastroenterol
July 2020
Purpose Of Review: In the context of the rising incidence and complexity of inflammatory bowel disease (IBD), telehealth offers new ways to support remote and efficient delivery of healthcare services. The aim of this review is to assess the current status of telehealth services in the management of IBD and challenges to adopting telehealth in clinical practice.
Recent Findings: Different modalities of telehealth such as virtual clinics and remote patient monitoring have been studied in many IBD centers.
Purpose Of Review: Telehealth is the delivery of health care using the most recent technological advances. With the growing complexity of inflammatory bowel disease (IBD) care, telehealth allows for delivery of specialty services to an extended population. We reviewed the most recent literature on telehealth modalities, including patient-reported and disease outcomes associated with use of telehealth.
View Article and Find Full Text PDFBackground: Tumor necrosis factor (TNF) antagonists used for the treatment of inflammatory bowel disease (IBD) have been associated with the development of psoriasiform skin lesions. We assessed the demographic and clinical characteristics associated with and outcomes of patients with anti-TNF-induced psoriasiform lesions.
Methods: Patients with Crohn's disease (CD) and ulcerative colitis (UC) receiving treatment with anti-TNF therapy (infliximab, adalimumab, or certolizumab pegol) at a tertiary referral center were identified using an IRB-approved clinical data repository.